To Proactively Address SDOH, the ‘Top of Funnel’ is Critical
December 20th 2022We can identify and engage the right people. But to make a real difference in any community, a managed care organization, government agency or healthcare system needs to have a robust list/dataset of its population so the tools, processes and individuals that come after can do the work to identify and engage members with the highest needs.
Read More
FDA Updates for the Week of Dec. 12, 2022
December 17th 2022In COVID-19 news, the FDA granted fast track designation to COVID-19-flu vaccine combo. The FDA has approved the first gene therapy for bladder cancer, an 8th biosimilar referencing Humira, granted accelerated approval for KRAS-mutated lung cancer therapy, and approved Iyuzeh to reduce intraocular pressure. The agency also extended review of Lynparza/abiraterone combination for prostate cancer. In addition, two companies have submitted applications: Soligenix for a novel therapy for cutaneous T-cell lymphoma and AbbVie for Linzess in children and adolescents.
Read More
Health Plan Executives Like Transparency Benefits, but Say Compliance is Complex
December 16th 2022Another component of the government’s Transparency in Coverage mandate and No Surprises Act legislation for health insurance plans will go into effect on January 1, 2023 for price transparency.
Read More
The Merging Market Today in Healthcare, According to Chuck Salvo of ToneyKorf Partners
December 15th 2022In this week's episode, Briana Contreras, an editor of Managed Healthcare Executive, spoke with Chuck Salvo managing director of ToneyKorf Partners. The pair touched on topics involving mergers between healthcare organizations, the question whether CEO's are being replaced and the importance of a board in a healthcare organization.
Listen
Differences in Patient Characteristics, Treatment of EoE by Allergists and Gastroenterologists
December 12th 2022Most (91%) of the patients were seen by gastroenterologists. Those seen by allergists were more likely to have comorbid atopic conditions, such as asthma, allergic rhinitis and atopic dermatitis.
Read More
Biocon Biologics Completes $3 Billion Acquisition of Viatris’ Biosimilars
December 12th 2022The acquisition provides Biocon Biologics with eight commercial biosimilars, and is part of Viatris’ efforts to pay down debt related to phase 1 research and the company’s acquisition of two ophthalmology businesses.
Read More
COVID Cases Are Less Harsh, Amid 'Certainly' Still Being in the Middle of a Pandemic
December 11th 2022Dr. Syra Madad of the NYC hospital system and an Infectious Disease Epidemiologist at Harvard's Belfer Center for Science and International Affairs responded to Dr. Anthony Fauci's, director of NIAID, statement made in late November that the U.S. is “certainly” still in the middle of a Covid-19 pandemic.
Read More
FDA Updates for the Week of Dec. 5, 2022
December 10th 2022In COVID-19 news, the FDA has expanded the updated bivalent vaccines EUA to children. The FDA has requested athe removal of Pepaxto indication for multiple myeloma. Regulators have also accepted several applications for: Biogen’s Actemra biosimilar, Pfizer’s RSV vaccine, a resubmitted BLA for Fabry disease. Two companies — Janssen’s and Alnylam — have submitted new applications.
Read More
Long-term Use of Dupixent Effective for Patients With Asthma Regardless of CRSwNP Status
December 9th 2022Patients with severe asthma with or without coexisting chronic rhinosinusitis and nasal polyps (CRSwNP) experienced continued improvements in exacerbations and lung function in an extension study.
Read More
Streamlining Medicare Advantage Enrollment is Key for Health Plans to Thrive During Surge
December 9th 2022As soon as next year, enrollment in Medicare Advantage plans are expected to exceed 50% of the entire Medicare eligible population. For the first time ever, the majority of Medicare beneficiaries will receive health benefits delivered by a private health plan, rather than through traditional, fee-for-service Medicare.
Read More
Variation by Age of EoE Symptoms May Contribute to Delayed Diagnosis for Some Patients
December 6th 2022Patients with eosinophilic esophagitis experience a range of symptoms that can vary by age, which may contribute to younger patients experiencing a delay in diagnosis, according to a poster presented at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting.
Read More
FDA Updates for the Week of Nov. 28, 2022
December 3rd 2022This week, the FDA made two approvals, the first-ever microbiota product and a second indication for Brexafemme, and issued a CRL for a therapy for brain metastasis from neuroblastoma. The regulatory agency also granted priority review for a Duchenne gene therapy, and accepted three applications: for a cutaneous T-cell lymphoma therapy, for an antibiotic for drug-resistant infections and Evkeeza for children with rare high cholesterol. Additionally, Genentech has withdrawn Tecentriq’s indication for bladder cancer and Aldeyra has submitted an NDA for the novel dry eye therapy reproxalap.
Read More
Demand Up, Supply Down = Adderall Shortage
December 1st 2022Short-term manufacturing problems are happening as the demand for Adderall and other stimulant medications for ADHD have increased. Data from Arrive Health show a marked increase in ADHD medication prescriptions for people in their 30s.
Read More
Use Quick Wins to Speed Your Healthcare Digital Transformation
November 29th 2022What does it take for a healthcare organization to effectively expedite and achieve a digital transformation? Start with the fundamentals, like having an integrated transformation strategy with clear goals across the enterprise, highly visible and vocal top-down leadership, and exceptional tactical talent for implementation.
Read More
Disrupting Healthcare from the Inside Out
November 27th 2022To truly transform healthcare, we must create a connected care journey: delivering care that meets patients where they are, when they need it, and continues to be personalized for them through their entire health journey, wherever that may lead next.
Read More
FDA Updates for the Week of November 21, 2022
November 26th 2022The FDA has approved a $3.5 million hemophilia B gene therapy and warned about Prolia in patients with kidney disease. The agency accepted for priority review two BLAs: for a dengue vaccine and for epcoritamab for large B-cell lymphoma. Additionally, GSK has pulled Blenrep from the U.S. market at the request of the FDA.
Read More